Mutational analysis of selected high-grade malignancies in a premenopausal gynecologic cancer population: a potential for targeted therapies?

Table 2 Epithelial Profile

n = 11				Genes associated with this histologic type^c
Age				APC	ERBB2	NRAS
Range	23–40			ARID1A	FBXW7	PIK3CA
Mean	33.9			BRAF	FGFR2	PPP2R1A
Median	36			BRCA1	KRAS	PTEN
BMI				BRCA2	MLH1	RNF43
Range	24–61.4			CDKN2A	MSH6	SMARCA4
Mean	34			CTNNB1	MYC	TP53
Median	30			DNMT3A	NF1
Survival
Range	369–660
Mean	542
Median	590
		Chemo	Rad	Alive	Novel Targets	Profiles
Location						n = 7^ab
Ovary	7 (64%)	Carbo/Taxol	0	5 (71%)	AKAP9 (3) CMPK (1) MBD1 (1) ASXL1 (1) ERBB3 (2) KMT2D (1)	ERBB3 only (1)^a AKAP9 only (3) CMPK, ASXL1 ERBB3 (1) MBD1, KMT2D (1) No significant genes (0)^b
Cervix	2 (18%)	Carbo/Taxol (1) Plat/Etop (1)	1 1	2 (100%)	0	n/a
Endometrial	2 (18%)	Carbo/Taxol	1	2 (100%)	CMPK (1) MBD1 (1) ROS1 (1) GPR124 (1)	CMPK, MBD1 (1) ROS1, GPR124 (1)

^aindicates these profiles are associated with negative outcomes in our cohort; ^bone patient failed to have mutations in a significant gene; ^cdata and sources retrieved from http://cancer.sanger.ac.uk/cosmic